References
- Dimopoulos M A, Palumbo A, Delasalle K B, Alexanian R. Primary plasma cell leukemia. Br J Haematol 1994; 88: 754–759
- Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565–1571
- Noel P, Kyle R A. Plasma cell leukaemia: an evaluation of response to therapy. Am J Med 1987; 83: 1062–1068
- Bladè J, Esteve J. Treatment approaches for relapsing and refractory multiple myeloma. Acta Oncol 2000; 39: 843–847
- Lee C K, Barlogie B, Zangari M, Fassas A, Anaissie E, Morris C, et al. Transplantation as salvage therapy for high-risk patients with myeloma in relapse. Bone Marrow 2002; 30: 873–878
- Vacca A, Ribatti D, Roncali L, Ranieri G, Serio G, Silvestris F, Dammacco F. Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol 1994; 87: 503–508
- Perez-Atayde A R, Sallan S E, Tedrow U, Connors S, Allured E N, Folkman J. Spectrum of tumour angiogenesis in the bone marrow of children with acute lymphocytic leukaemia. Am J Pathol 1997; 150: 815–821
- D'Amato R J, Loughnan M S, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994; 1: 4082–4085
- Kumar S, Witzig T E, Dispenzieri A, Lacy M Q, Wellik R E, Fonseca R, et al. Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma. Leukaemia 2004; 18: 624–627
- Bladé J, Perales M, Rosino L, Tuset M, Montoto S, Esteve J, et al. Thalidomide in multiple myeloma: lack of response of soft-tissue plasmacytomas. Br J Haematol 2001; 113: 422–424
- Rajkumar S V, Hayman S, Gertz M A, Dispenzieri A, Lacy M Q, Greipp P R, et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002; 20: 4319–4323
- Anagnostopoulos A, Weber D, Rankin K, Dellasalle K, Alexanian R. Thalidomide and dexametasone for resistant multiple myeloma. Br J Haematol 2003; 21: 768–771
- Moehler T M, Neben K, Benner A, Egerer G, Krasniqi F, Ho A D, et al. Thalidomide plus CED chemotherapy as salvage therapy in poor prognosis multiple myeloma. Blood 2001; 15: 3846–3848
- Cavo M, Zamagni E, Tosi P, Tacchetti P, Cellini C, Cangini D, et al. Superiority of thalidomide and dexamethasone over Vincristine-doxorubicin-dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 2005; 106: 35–39
- Zangari M, Siegel E, Barlogie B, Anaissie E, Saghafifar F, Fassas A, et al. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood 2002; 100: 1168–1171